The prognostic value of genetic alterations characteristic of glioblastoma in patients treated according to present standards of care is unclear.
INTRODUCTION
Numerous chromosomal, genetic, and epigenetic aberrations occur at more than random frequency in gliomas. 1 However, the clinical value of most glioma-associated molecular aberrations in terms of their significance as diagnostic, prognostic, or predictive molecular markers has remained unclear. [2] [3] [4] [5] To date, only two molecular aberrations have been demonstrated to be of clinical significance in prospective clinical trials. Allelic losses on chromosome arms 1p and 19q are associated with a favorable prognosis in patients with oligodendroglial and oligoastrocytic anaplastic gliomas treated with radiotherapy or radiotherapy plus chemotherapy.
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MGMT promoter hypermethylation is associated with prolonged progression-free survival (PFS) and overall survival (OS) in patients with glioblastoma treated with alkylating agents such as nitrosoureas or temozolomide. [10] [11] [12] [13] To systematically investigate the prognostic significance of molecular genetic markers in gliomas beyond known clinical prognostic factors, we determined a set of common gliomaassociated aberrations in a prospective manner for each patient with glioblastoma recruited into the German Glioma Network (GGN).
PATIENTS AND METHODS

Patients
The patients were prospectively enrolled in the clinical centers of the GGN: Bonn, Dresden, Freiburg, Hamburg, LMU Munich, and Tübingen. The GGN is a clinical research network sponsored by the German Cancer Aid (Deutsche Krebshilfe), which in addition to the above-mentioned clinical centers includes associated centers for central neuropathology review in Bonn, molecular neuropathology in Düsseldorf and Heidelberg, and biometry in Leipzig. The GGN aims at enrolling all adult patients with gliomas seen at these centers since October 2004. Fresh-frozen tissue and blood samples are obtained from all patients with microsurgical tumor resection and clinical follow-up information is collected on electronic case report forms in regular intervals (www.gliomnetzwerk.de). All activities of the GGN have been approved by the review boards of the participating institutions. Recruitment is ongoing. The data presented here include consecutive patients included until December 2006.
Central Reference Pathology
Formalin-fixed, paraffin-embedded material of all 301 patients was submitted from the local (neuro)pathologists of the GGN centers for an independent histopathologic review to the German Brain Tumor Reference Center in Bonn. Four-m sections were cut and conventional hematoxylin and eosin and silver impregnation (Gomori) stainings and basic immunohistochemical reactions for protein expression including glial fibrillary acidic protein (polyclonal rabbit antibody, Dako, Hamburg, Germany, 1: 500 dilution), p53 (monoclonal murine, clone DO7, Dako, 1:70 dilution, microwave pretreatment with citrate buffer pH 6.0), and Ki-67 (monoclonal murine, clone Mib-1, Dako, 1:50 dilution, microwave pretreatment with citrate buffer pH 6.0) were performed. Binding of the first antibody was detected by the avidin-biotinperoxidase method and diaminobenzidine peroxidase substrate. Staining was graded according to the percentages of stained tumor cells as absent, weak (Ͻ 30%), or strong (Ͼ 30%). For correlation with other molecular markers, we compared absent and weak versus strong staining.
All tumors were classified according to the WHO classification of tumors of the CNS. [14] [15] Essential characteristics including the presence or absence of necrosis, pseudopalisading perinecrotic cells, microvascular proliferation, giant cells, oligodendroglial-like, sarcomatous, neuronal or other components, and Ki-67 proliferation index were scored. If the final classification of the tumor was different between local and central reference center, the reference diagnosis overruled the local diagnosis for data analysis.
Extraction of Nucleic Acids
Tumor samples were immediately frozen in liquid nitrogen and stored at Ϫ80°C. From each patient, a peripheral blood sample was drawn and stored at Ϫ80°C. Only specimens with an estimated tumor cell content of 80% or more were used for molecular analyses. DNA extraction was carried out using blood and tissue DNA extraction kits (Qiagen, Hilden, Germany).
MGMT Promoter Methylation Analysis
MGMT promoter methylation status was determined by methylationspecific polymerase chain reaction (PCR), [16] [17] using the following primer sequences to amplify sequences from the methylated or unmethylated MGMT promoter: 5Ј-GTTTTTAGAACGTTTTGCGTTTCGAC-3Ј and 5Ј-CACCG-TCCCGAAAAAAAACTCCG-3Ј or 5Ј-TGTGTTTTTAGAATGTTTTGTG-TTTTGAT-3Ј and 5Ј-CTACCACCATCCCAAAAAAAAACTCCA-3Ј. A172 glioma cells, obtained from American Type Culture Collection, and peripheral blood DNA served as positive and negative controls. A further control reaction without template DNA was performed together with each PCR experiment.
TP53 Mutation Analysis
To amplify TP53 exons 5 to 8, PCR was performed in a volume of 10 L containing 10 ng of DNA, 50 mmol/L KCl, 10 mmol/L Tris-HCl, 200 mmol/L each dNTP, 0.1% gelatin, 20 pmol of each primer, 1 to 2 mmol/L MgCl 2 , and 0.025 U Taq polymerase. The primer sequences were exon 5a 5Ј-TCAACT-CTGTCTCCTTCCTC-3Ј and 5Ј-CTGTGACTGCTTGTAGATGG-3Ј; exon 5b 5Ј-GTGGGTTGATTCCACACCCC-3Ј and 5Ј-AACCAGCCCTGTCG-TCTCTC-3Ј; exon 6 5Ј-AGGCCTCTGATTCCTCACTG-3Ј and 5Ј-AGAG-ACCCCAGTTGCAAACC-3Ј; exon 7 5Ј-GGCCTCATCTTGGGCCTGTG-3Ј and 5Ј-GTGTGCAGGGTGGCAAGTGG-3Ј; exon 8 5Ј-AATGGGACA-GGTAGGACCTG-3Ј and 5Ј-ACCGCTTCTTGTCCTGCTTG-3Ј. The PCR conditions on an automated thermal cycler (Biometra, Göttingen, Germany) were initially 94°C for 3 minutes followed by 30 cycles at 94°C/30 seconds, 57°C/40 seconds, and extension at 72°C for 40 seconds. A final extension step at 72°C for 10 minutes was added. Single strand conformation polymorphism analysis was performed on a sequencing apparatus (BlueSeq 400; Serva, Marburg, Germany) using 8% and 14% acrylamide gels and electrophoresis at 3 to 6 W for 15 hours followed by silver staining of the gels. Aberrantly migrating bands were excised and DNA was extracted. After reamplification with the same set of primers the PCR products were sequenced on a semiautomated sequencer (ABI 3100, Applied Biosystems, Foster City, CA) using a Taq cycle sequencing kit (Applied Biosystems). Each amplicon was sequenced bidirectionally.
Determination of EGFR, CDK4, MDM2, and CDKN2A Gene Dosages
EGFR amplification was demonstrated by real-time PCR using the ABI PRISM 5700 sequence detection system (Applied Biosystems). The EGFR gene dosage was normalized to the dosage of the marker D2S1743 at 2q21.2. The following oligonucleotide primers were used: EGFR, 5ЈCACTTGCCTCA-TCTCTCACCATC-3Ј and 5Ј-GACTCACCGTAGCTCCAGAC-3Ј (110 bp); D2S1743, 5Ј-CATGACTGCGAGCCCAAGATG-3Ј and 5Ј-CAGGTGG-TGTCATCAGAATCAG-3Ј (131 bp). Gene dosages of MDM2, CDK4, and CDKN2A were determined by duplex PCR assays, using the following primers: 5Ј-GCGATGAATTGATGCTAATGAATG-3Ј and 5Ј-CAGGATCTTCTTC-AAATGAATCTG-3Ј for a 99 bp MDM2 amplicon; 5Ј-GACTGCTA-CCTTATATCCCTTC-3Ј and 5Ј-CTCCCATGTTGGTCACTTAC-3Ј for a 102 bp CDK4 amplicon and 5Ј-GAAGAAAGAGGAGGGGCTG-3Ј and 5Ј-GCGCTACCTGATTTCAATTC-3Ј for a 338 bp CDKN2A amplicon. The reference locus was APRT (5Ј-CTGGAGCACCTGCTCTCTGC-3Ј and 5Ј-GCCCTGTGGTCACTCATACTGC-3Ј, 211 bp amplicon). Positive controls included a glioblastoma with MDM2 and CDK4 amplification previously demonstrated by Southern blot analysis 18 and the glioblastoma cell line U118MG which carries a homozygous CDKN2A deletion. DNA extracted from non-neoplastic brain tissue and peripheral blood leukocytes served as constitutional reference. PCR products were separated on 3% agarose gels, and the ethidium bromide-stained bands were recorded using the Gel-Doc 1000 system (BioRad, Hercules, CA). Quantitative analysis of the signals obtained for the target and the reference genes was performed with the MolecularAnalyst software (BioRad). Increases in the target (CDK4 and MDM2) to reference gene ratio of more than five-fold of the ratio obtained for the constitutional DNA were considered as gene amplification. Decreases in the target (CDKN2A) to reference gene ratio of equal to or less than 0.3-fold of the ratio obtained for the constitutional DNA were considered as homozygous deletion.
Microsatellite and IDH1 Analyses
The following microsatellite loci were investigated for loss of heterozygosity in each tumor: 1p: D1S1608 (1p36.31), D1S548 (1p36.31), D1S1592 (1p36.13), DS1161 (1p35.2) and D1S1184 (1p31.3); 9p: D9S171 (9p21.3), D9S168 (9p23), and D9S162 (9p22.1); 10q: D10S541 (10q23.31), D10S209 (10q26.12), and D10S212 (10q26.3); 19q: 32) , and D19S601 (19q13.41). PCR amplification of these microsatellite markers was carried out as reported. [19] [20] The PCR products were separated by electrophoresis on denaturing polyacrylamide gels and visualized by silver staining. The allele patterns were assessed for allelic imbalance.
9,20 IDH1 mutations were assessed as previously described.
Statistical Analyses
Statistical analysis was done using the statistical software R (http:// www.r-project.org/). The Mann-Whitney U, 2 , and Fisher's exact tests were used to test for association of clinical variables and molecular markers. The log-rank test was used to test for survival differences among groups. The false discovery rate method 22 was used to adjust P values for multiple testing of correlations between molecular markers and their associations with PFS and OS. PFS was calculated from the day of first surgery until tumor progression, death, or end of follow-up. OS was calculated from the day of first surgery until death or end of follow-up. The effect of each single molecular marker on PFS and OS was investigated using the Cox proportional hazards model, adjusting for the major clinical prognostic factors age at diagnosis (Ͻ 60 v Ն 60 years), Karnofsky performance score (KPS; Ͻ 80 v Ն 80), extent of resection (total v nontotal), MGMT promoter methylation status, and adjuvant therapy (radiotherapy alone v radiotherapy plus temozolomide). The multivariate model was applied to all patients who had complete information on the five clinical factors named above and who received radiotherapy alone or radiotherapy plus temozolomide as their first-line therapy. The models presented are calculated without taking interactions terms into account. Variants of the multivariate model including interactions between age, MGMT, and temozolomide were evaluated in a sensitivity analysis, but did not show qualitatively different results regarding the prognostic value of the molecular markers. Radiation Therapy Oncology Group recursive partitioning analysis classes were assessed as described. 23 
RESULTS
Clinical Parameters
The study population comprised 291 patients with glioblastoma, eight with giant cell glioblastoma and two with gliosarcoma, for a total of 301 patients. The median follow-up was 29.4 months and 238 patients died. Clinical patient characteristics are summarized in Table  1 . There were no significant differences for any of these parameters between male and female patients, except for a trend to younger age in male patients (51% v 39%; Ͻ 60 years in male and female patients; P ϭ .045). The median ages for patients treated with radiotherapy plus temozolomide versus radiotherapy alone were 58. The median PFS for all patients was 6.8 months (95% CI, 6.2 to 7.3). The median OS was 12.5 months (95% CI, 11.1 to 14.3). The prognostic relevance of the clinical parameters age, KPS, and extent of resection is summarized in Table 2 , as is the prognostic Figures 1A and 1B . The PFS data for patients receiving radiotherapy alone (n ϭ 64) may be overestimated, given that 30% of these patients had no documented progression before death, whereas this was the case for only 6% of the patients starting on temozolomide radiochemotherapy. Hence, follow-up documentation may have been less vigorous in patients managed with radiotherapy alone.
Molecular Parameters
Glioblastoma-associated molecular aberrations were observed with the following frequencies: TP53 mutation 15%, EGFR amplification 40%, CDK4 amplification 10%, MDM2 amplification 6%, CDKN2A homozygous deletion 19%, allelic losses on chromosome arms 1p 21%, 9p 41%, 10q 58%, 19q 19%, and 1pϩ19q 8% (Table 3) . None of these aberrations was associated with the clinical parameters age, KPS, or extent of resection (data not shown) or PFS or OS (Fig 2; Appendix Table A1 , online only). This was true for all patients as well as for the subpopulations receiving radiotherapy alone, radiotherapy and temozolomide, or any of these therapies after correcting for multiple testing. Various associations of these molecular parameters were confirmed. A complete overview of the pairwise associations between these molecular markers and MGMT status is given in Appendix Table  A2 (online only).
MGMT promoter methylation was detected in 44% of the patients and conferred superior PFS and OS (Appendix Table A1 ). The MGMT status was not associated with the clinical parameters age, KPS, or extent of resection, nor with the first-line treatment administered. Moreover, MGMT promoter methylation status was not associated with any of the molecular parameters tested here (Appendix Table A2 ). MGMT promoter methylation did not translate into a significant prolongation of PFS in patients receiving radiotherapy alone as their first-line treatment. In contrast, MGMT promoter methylation was strongly associated with longer PFS and OS in patients receiving temozolomide ( Figs 1C and 1D) . We also tested for interactions between MGMT promotor methylation and single molecular factors regarding PFS and OS, but did not find any relevant interaction (data not shown). IDH1 mutations were found in 16 of 286 patients tested in our data set. They were associated with prolonged PFS and OS on univariate analysis (Appendix Table A1 ) and correlated positively with p53 immunoreactivity, but negatively with EGFR amplification and 10q loss (Appendix Table A2 ).
Multivariate Analyses for Outcome
We established multivariate survival models for PFS and OS including the prognostic factors age at diagnosis, KPS, extent of resection, MGMT promoter methylation status, and adjuvant therapy. These analyses were restricted to the two patient populations receiving either radiotherapy alone or radiotherapy plus temozolomide as their first-line treatment with full information on all clinical parameters (229 patients; Table 1 ). The models were designed to take each of the factors into account without considering interaction terms.
Independent prognostic factors for PFS were age and MGMT status, and for OS were age, KPS, MGMT status, and type of adjuvant therapy (Table 4) . These multivariate models for PFS and OS using age, KPS, extent of resection, MGMT status, and adjuvant therapy were subsequently used as adjustments for estimating the relative risk (RR) associated with the effect of single molecular parameters besides MGMT. Relative risk estimates and CIs are summarized in Appendix Figure A1 (online only). Among the 11 molecular markers investigated, only IDH1 mutation status was associated with prolonged PFS (RR, 0.42; 95% CI, 0.19 to 0.91; P ϭ .028) and a trend for improved OS (RR, 0.43; 95% CI, 0.15 to 1.19; P ϭ .10). All other markers were not associated with PFS or OS.
In a sensitivity analysis, we investigated whether more extended multivariate models also considering possible two-way interactions between age, MGMT status, and treatment modality-radiotherapy only or radiotherapy plus temozolomide-would impact this conclusion. Although we found some indications for interactions (eg, of age and MGMT status; data not shown), all estimates on the molecular markers remained very similar to those shown in Appendix Figure 1 with a general tendency to shrink towards the relative risk of 1. Hence, the estimates shown are the least conservative.
DISCUSSION
The GGN aims at generating a database for the diagnosis, treatment, and follow-up of patients with glioma at several large academic centers as well as a tissue bank for translational research. This study focused on the prognostic significance of established molecular markers in patients with glioblastoma enrolled in the first 27 months of funding. The major strengths include the following: clinical data were collected prospectively, patients were enrolled within a short time frame, clinical data were obtained in the temozolomide era which makes them particularly relevant for contemporary neuro-oncology, we studied not only OS, but also PFS, and both end points were stratified by treatment.
We confirm the major therapy-independent prognostic factors age and KPS. Extent of resection was only of prognostic value when completely resected patients were compared with all other patients ( Table 2 ) and on univariate analysis only (Table 4) . In contrast, all molecular aberrations attributed a role in the development of glioblastoma, including TP53 mutation, EGFR amplification, CDK4 amplification, MDM2 amplification, CDKN2A homozygous deletion, LOH 1p, LOH 9p, LOH 10q, LOH 19q or 1p/19q codeletion, were not associated with PFS and OS (Appendix Table A1 , Fig 2) . When controlled for age, neither of the parameters examined had a prognostic impact in the Boston (TP53, EGFR, CDKN2A, LOH 1p, 10q, 19q) 2 or Duke (TP53, EGFR, CDKN2A, PTEN) 4 series. An association of LOH 10q with poorer survival was identified in the Zurich series 3 whereas EGFR amplification was associated with better survival in the Paris series 5 (Table 3) . As a result of the European Organisation for the Research and Treatment of Cancer National Cancer Institute of Cancer trial, 24 temozolomide is now the chemotherapeutic agent most commonly used in patients with newly diagnosed glioblastoma ( Table 1, Figs 1A and 1B). We confirm that MGMT promoter methylation is a strong predictor of prolonged PFS and OS in patients receiving temozolomide ( Figs 1C and 1D) . Similarly, in a French series, MGMT promoter This study may also have clarified the controversial interrelation of MGMT promoter methylation and p53 status. p53 immunoreactivity suggestive of TP53 mutations has been linked to low MGMT mRNA expression, 26 but did not correlate with MGMT promoter methylation. 25 We observed that abrogation of wild-type p53 function in cultured glioma cells greatly attenuated sensitivity to temozolomide, whereas a p53 mimetic small molecule enhanced temozolomide sensitivity. 27 The extensive analysis here suggested a trend that patients with TP53 mutations derived more benefit from temozolomide chemotherapy than patients with TP53 wildtype tumors, but overall no significant association between MGMT promoter methylation and p53 status became apparent (data not shown).
Future approaches likely to yield novel predictors of response to therapy and outcome include global analyses of gene expression profiling 4,28 and genomic 29 and epigenetic 30 profiling. High throughput analyses have recently resulted in the identification of mutations in the active site of the IDH1 gene as a novel prognostic marker in gliomas. 21, [31] [32] This study supports the hypothesis that within the group of primary glioblastomas, IDH1 mutations are rare and define a prognostically favorable subgroup (Fig 2) .
In summary, we demonstrate here that genetic changes commonly associated with the pathogenesis of gliomas do not predict response to therapy in patients with glioblastoma managed according to current standards of care. MGMT promoter methylation status is clinically the most relevant molecular parameter and should be included as a stratification factor in all future trials in glioblastoma. 
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